Lilly reorganizes venture capital unit
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.
Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force,
with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though
it’s far from the lucrative payoff they’d once imagined.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Corporate boards need more women, but not people such as Susan Bayh, wife of Sen. Evan Bayh. It’s not
that she isn’t up to the task. The former attorney at Eli Lilly and Co. and visiting professor at Butler University
is by all accounts capable. So we’re not surprised she regularly receives invitations to serve on boards. But
we are surprised she accepts.
The Indianapolis Convention and Visitors Association is putting together an all-star corporate consortium to make the city
a hub for medical and life sciences conventions, meetings and trade shows. The ICVA began running the initiative
full-speed this year and already has signed deals to bring 40 medical meetings to Indianapolis through 2015, including annual
meetings for the American Association of Diabetes Educators in 2012 and the American College of Sports Medicine and American
Chemical Society in 2013.
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total
of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way
of Central Indiana a total of $1 million over the next four years as a “challenge to CEOs and other community leaders to step
up their giving.”
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Eli Lilly and Co. watched $97 million and a whole lot of hope wash down the drain yesterday. The Indianapolis-based drugmaker and a development partner canceled clinical trials on an experimental drug to treat multiple sclerosis when the drug failed to delay progression of the disease in clinical trial patients. Lilly had partnered with the […]
Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today.Lilly can now promote Forteo as a therapy for men and women who regularly take medicines called glucocorticoids for rheumatory arthritis or obstructive lung disease. Sustained use of glucocorticoids cause bone fractures in […]
MoveSmart LLC works with business clients looking to make better use of their space, helping to design, furnish and adapt
their offices for maximum efficiency.
Eli Lilly and Co. will relocate the research offices of its ImClone subsidiary into a new bioscience park developed by New York City. Indianapolis-based Lilly will be the first tenant in the new East River Science Park, according to an announcement made this afternoon by New York Mayor Michael Bloomberg and Lilly CEO John Lechleiter. […]
Investors and analysts brushed off the 21-percent quarterly profit growth announced by Eli Lilly and Co. this morning and focused on the company’s launch of its new blood-thinning drug Effient. Shares of the Indianapolis-based drugmaker were flat in morning trading, in line with broader markets, even though Lilly boosted its year-end profit forecast by a […]
Second-quarter profit rose 21 percent at Eli Lilly and Co., helping the company beat the expectations of Wall Street analysts and raise its year-end profit forecast. The Indianapolis-based drugmaker earned $1.16 billion, or $1.06 per share, including a $105 million after-tax charge Lilly recorded to prepare for an expected legal settlement involving its bestseller Zyprexa. […]
Could Eli Lilly be getting some revenge in the diabetes market? The Indianapolis drugmaker released clinical trial data today showing that its long-acting version of Byetta helped patients reduce their blood sugar and weight better than the long-acting insulin Lantus. Lantus, made by France-based Sanofi-Aventis SA, is a drug that stole significant insulin market share […]
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Health care marketers can adapt to, and even use to their advantage, the online search habits of consumers.
Understanding when and why people search for specific health-related terms is vital to attracting more
visitors (i.e. patients) to a Web site.
Indianapolis-based Eli Lilly and Co. and four of its peers have to submit second bids this week in a scramble to acquire the animal health businesses of two other drugmakers, Merck & Co. Inc. and Schering-Plough Corp. The final decision on who gets what and at what price is expected by the end of July, […]